Tumor and peripheral blood samples from 32 glioma patients (WHO 2021 classification, grades II-IV) were analyzed by flow cytometry to assess ILC subsets and immunecheckpoint molecules (PD-1, CTLA-4, KLRG1). Here, CTLA4 is linked to glioma.